Prof Gavin Churchyard - The Aurum Institute

Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis

Vesga, J.F., Lienhardt, C., Nsengiyumva, P., Campbell, J.R., Oxlade, O., den Boon, S., Falzon, D., Schwartzman, K., Churchyard, G. and Arinaminpathy, N., 2022. Prioritising attributes for tuberculosis...
Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition

Bender Ignacio, R.A., Long, J., Saha, A., Nguyen, F.K., Joudeh, L., Valinetz, E., Mendelsohn, S.C., Scriba, T.J., Hatherill, M., Janes, H. and Churchyard, G., 2022. Mycobacterium tuberculosis infectio...
Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study.

Mulenga, H., Fiore-Gartland, A., Mendelsohn, S.C., Penn-Nicholson, A., Mbandi, S.K., Nemes, E., Borate, B., Musvosvi, M., Tameris, M., Walzl, G. and Naidoo, K., 2022. Evaluation of a transcriptomic si...
WHO target product profiles for TB preventive treatment

Den Boon, S., Lienhardt, C., Zignol, M., Schwartzman, K., Arinaminpathy, N., Campbell, J.R., Nahid, P., Penazzato, M., Menzies, D., Vesga, J.F. and Oxlade, O., 2022. WHO target product profiles for T...
The NIH/DAIDS Cross-Network TB Vaccine Working Group calls for people living with HIV to be included in tuberculosis vaccine development

...
TB contact tracing helps save lives — this is how it works in SA

...
NRF awards SA’s top researchers, scientists for 2023

...
What's behind the debate to re-authorize PEPFAR, the widely hailed anti-HIV effort?

...
US Aids fund: What is the Pepfar fight and what does it mean for Africa?

...
Prof. Gavin Churchyard receives A-rating from National Research Foundation

South Africa’s National Research Foundation has released its rating of researchers as part of its goal to develop an internationally competitive scientific research system. Aurum Group CEO Prof Gavi...
New Child-friendly TB Prevention Treatment Available

...
Kenyan children at risk of TB to get sweet prevention drugs

...
What is next for BCG revaccination to prevent tuberculosis?

White, R.G., Fiore-Gartland, A.J., Hanekom, W.A., Vekemans, J., Garcia-Basteiro, A.L., Churchyard, G., Rangaka, M.X., Frick, M., Behr, M.A., Hill, P.C. and Mave, V., 2024. What is next for BCG revacci...
Aurum Leadership Roadshow takes Klerksdorp

Aurum Leadership is on the move once again, and this time we've joined forces with the remarkable Aurum Klerksdorp Clinical Research and Health Systems. Opening the day, Group CEO, Prof Gavin Churchy...
Circulating Biomarkers, Fraction of Exhaled Nitric Oxide, and Lung Function in Patients With Human Immunodeficiency Virus and Tuberculosis.

Maenetje P, Baik Y, Schramm DB, Vangu MDW, Wallis RS, Mlotshwa M, Tiemessen CT, Li Y, Kornfeld H, Churchyard G, Auld SC, Bisson GP. Circulating Biomarkers, Fraction of Exhaled Nitric Oxide, and Lung F...
Reply to McShane.

Hill, P.C., Cobelens, F., Martinez, L., Garcia-Basteiro, A.L., Behr, M.A., Rangaka, M.X., Churchyard, G., Evans, T., Hanekom, W. and White, R.G., 2024. Reply to McShane. The Journal of Infectious Dis...
. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment.

Rangaka, M.X., Frick, M., Churchyard, G., García-Basteiro, A.L., Hatherill, M., Hanekom, W., Hill, P.C., Hamada, Y., Quaife, M., Vekemans, J. and White, R.G., 2023. Clinical trials of tuberculosis va...
Lung function and collagen 1a levels are associated with changes in 6 min walk test distance during treatment of TB among HIV-infected adults: A prospective cohort study.

Baik, Y., Maenetje, P., Schramm, D., Tiemessen, C., Ncube, I., Churchyard, G., Wallis, R., Vangu, M.D.T., Kornfeld, H., Li, Y. and Auld, S.C., 2023. Lung function and collagen 1a levels are associated...
High isoniazid exposures when administered with Rifapentine once weekly for latent tuberculosis in individuals with human immunodeficiency virus.

Jarrett, R.T., van der Heijden, Y., Shotwell, M.S., Chihota, V., Marzinke, M.A., Chaisson, R.E., Dooley, K.E. and Churchyard, G.J., 2023. High isoniazid exposures when administered with rifapentine on...
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, p

Borges, Á.H. et al. (2025) ‘Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV‐negative adults successfully treated for dr...

Prioritising attributes for tuberculosis preventive treatment regimens: a modelling analysis

Mycobacterium tuberculosis infection, immune activation, and risk of HIV acquisition

Evaluation of a transcriptomic signature of tuberculosis risk in combination with an interferon gamma release assay: A diagnostic test accuracy study.

WHO target product profiles for TB preventive treatment

The NIH/DAIDS Cross-Network TB Vaccine Working Group calls for people living with HIV to be included in tuberculosis vaccine development

TB contact tracing helps save lives — this is how it works in SA

NRF awards SA’s top researchers, scientists for 2023

What's behind the debate to re-authorize PEPFAR, the widely hailed anti-HIV effort?

US Aids fund: What is the Pepfar fight and what does it mean for Africa?

Prof. Gavin Churchyard receives A-rating from National Research Foundation

New Child-friendly TB Prevention Treatment Available

Kenyan children at risk of TB to get sweet prevention drugs

What is next for BCG revaccination to prevent tuberculosis?

Aurum Leadership Roadshow takes Klerksdorp

Circulating Biomarkers, Fraction of Exhaled Nitric Oxide, and Lung Function in Patients With Human Immunodeficiency Virus and Tuberculosis.

Reply to McShane.

. Clinical trials of tuberculosis vaccines in the era of increased access to preventive antibiotic treatment.

Lung function and collagen 1a levels are associated with changes in 6 min walk test distance during treatment of TB among HIV-infected adults: A prospective cohort study.

High isoniazid exposures when administered with Rifapentine once weekly for latent tuberculosis in individuals with human immunodeficiency virus.

Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, p

Popular Tags

Most Read

Recent Posts